menu
    • menu
    [{"orgOrder":0,"company":"Kwangdong Pharmaceutical","sponsor":"Ocugen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Licensing Agreement","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kwangdong Pharmaceutical","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Kwangdong Pharmaceutical \/ Kwangdong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kwangdong Pharmaceutical \/ Kwangdong Pharmaceutical"}]

    Find Clinical Drug Pipeline Developments & Deals by Kwangdong Pharmaceutical

    Menu

    Kwangdong Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kwangdong Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Kwangdong Pharmaceutical

                            South Korea arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OCU400

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Ocugen

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ocugen and Kwangdong Complete License Agreement of OCU400 Modifier Gene Therapy

                            Details : Kwangdong gains exclusive Korean rights to OCU400, Ocugen’s novel modifier gene therapy for retinitis pigmentosa (RP).

                            Product Name : OCU400

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 15, 2025

                            Lead Product(s) : OCU400

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Ocugen

                            Deal Size : $7.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth